Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms

뉴스 본문을 불러오고 있어요.

Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms | 웨이프 WAPE

Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms

기사 요약

관련 종목

댓글 —